Security
Polyrizon Ltd. Ordinary Shares · PLRZ
PLRZNASDAQCommon stockCurrentCIK 1893645Updated Oct 8, 2026
PLRZ price & chart
Loading TradingView…
NASDAQ:PLRZ on TradingView ↗About the company
We are a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Our proprietary Capture and Contain™, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. We are further developing certain aspects of our proprietary C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. We refer to our separate platform technology that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T.
In the news
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 21,437,000Source | 5,547,000Source | 559,000Source |
| Property, Plant and Equipment, NetUSD | 12,000Source | 10,000Source | 12,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 2,547,000Source | 2,884,000Source | — |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 1,306,000Source | 2,554,000Source | 4,000Source |
| Assets, CurrentUSD | 12,860,000Source | 2,653,000Source | 54,000Source |
| LIABILITIES AND EQUITY | |||
| Stockholders’ equity: | |||
| Additional Paid in CapitalUSD | 29,395,000Source | 10,352,000Source | 3,526,000Source |
| Retained Earnings (Accumulated Deficit)USD | -8,401,000Source | -5,066,000Source | -3,521,000Source |
| Stockholders' Equity Attributable to ParentUSD | 20,994,000Source | 5,286,000Source | -191,000Source |
| Liabilities and EquityUSD | 21,437,000Source | 5,547,000Source | 559,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 443,000Source | 261,000Source | 502,000Source |
| Additional Financial Items | |||
| Short-term InvestmentsUSD | — | — | 37,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,310,000Source | 51,000Source | 100,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -4,528,000Source | -1,147,000Source | -537,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -16,534,000Source | 29,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 7,000Source | — | — |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 19,814,000Source | 3,668,000Source | 505,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,306,000Source | 2,554,000Source | 4,000Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 1,310,000Source | 51,000Source | 100,000Source |
| Amortization of Intangible AssetsUSD | 300,000Source | — | — |
| DepreciationUSD | 342,000Source | 118,000Source | 4,000Source |
| General and Administrative ExpenseUSD | 4,116,000Source | 768,000Source | 303,000Source |
| Net Income (Loss) Attributable to ParentUSD | -3,335,000Source | -1,545,000Source | -600,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 3,335,000Source | 1,605,000Source | 669,000Source |
| Nonoperating Income (Expense)USD | -2,914,000Source | 243,000Source | -35,000Source |
| Other Nonoperating Income (Expense)USD | -2,914,000Source | 243,000Source | -35,000Source |
| Proceeds from Issuance of Common StockUSD | — | 266,000Source | 256,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating Income (Loss)USD | -6,249,000Source | -1,302,000Source | -635,000Source |
| Other Nonoperating Income (Expense)USD | -2,914,000Source | 243,000Source | -35,000Source |
| Net Income (Loss) Attributable to ParentUSD | -3,335,000Source | -1,545,000Source | -600,000Source |
| Earnings Per Share, BasicUSD per share | 4.9Source | 0.5Source | 0.3Source |
| Earnings Per Share, DilutedUSD per share | 4.9Source | 0.5Source | 0.3Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 680,380Source | 2,991,193Source | 2,030,327Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 680,380Source | 2,991,193Source | 2,030,327Source |
| Additional Financial Items | |||
| Amortization of Intangible AssetsUSD | 300,000Source | — | — |
| General and Administrative ExpenseUSD | 4,116,000Source | 768,000Source | 303,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | -370,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 3,335,000Source | 1,605,000Source | 669,000Source |
| Nonoperating Income (Expense)USD | -2,914,000Source | 243,000Source | -35,000Source |
| Other ExpensesUSD | 464,000Source | — | — |
| Research and Development ExpenseUSD | 2,133,000Source | 534,000Source | 332,000Source |
Offerings
Registration 333-299014
Registration 333-295271
Filing attachments
ea030768701ex99-1.htm · 6-K · 2026-10-05
Exhibit 99.1 Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform A new patent application covers Polyrizon’s proprietary mucoadhesive platform and its potential applications in nasal drug delivery. Raanana, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a clinical-stage biotechnology company specializing in the development of innovative intranasal hydrogels, today announced that it has …
Read attachment ↗ea030456801ex99-1.htm · 6-K · 2026-09-28
Exhibit 99.1 POLYRIZON LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2026 UNAUDITED U.S. DOLLARS IN THOUSANDS INDEX Page Condensed Consolidated Balance Sheets F-2 Condensed Consolidated Statements of Comprehensive Loss F-3 Condensed Consolidated Statement of Changes in Shareholders’ Equity F-4 Condensed Consolidated Statements of Cas…
Read attachment ↗ea030456801ex99-2.htm · 6-K · 2026-09-28
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in this Form 6-K and our Annual Report on Form 20-F for the year ended December 31, 2025 (the “2025 Annual Report”). Unless the context requires otherwise, the terms “Polyrizon,” “we,” “us,” “our,” “the Company,” and similar designations refer to Polyrizon Ltd. Re…
Read attachment ↗ea030468601ex99-1.htm · 6-K · 2026-09-04
Exhibit 99.1 Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement RAANANA, ISRAEL, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the closing of its previously announced registered direct offering and concurrent private placement. The Company issued to a single institutional investor Ordinary Shar…
Read attachment ↗ea030232201ex99-1.htm · 6-K · 2026-09-04
Exhibit 99.1 Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement RAANANA, ISRAEL, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has entered into definitive agreements with a single institutional investor for the purchase and sale of its Ordinary Shares and pre-funded warrants in a registered direct…
Read attachment ↗ea030285302ex99-1.htm · 6-K · 2026-08-20
Exhibit 99.1 Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment Polyrizon completes contracting with all five U.S. clinical sites and advances its NASARIX™ study toward enrollment of 120 patients Raanana, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has complet…
Read attachment ↗